[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7288 Introduced in House (IH)]
<DOC>
116th CONGRESS
2d Session
H. R. 7288
To direct the Secretary of Health and Human Services and other Federal
officials to compile into a searchable database information relating to
Federal support for biomedical research and development related to
COVID-19, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 22, 2020
Mr. Doggett (for himself, Mr. Rooney of Florida, Ms. Schakowsky, Ms.
DeLauro, Mr. DeFazio, Mr. Pocan, and Ms. Jayapal) introduced the
following bill; which was referred to the Committee on Energy and
Commerce, and in addition to the Committees on Armed Services,
Veterans' Affairs, Science, Space, and Technology, the Judiciary, and
Ways and Means, for a period to be subsequently determined by the
Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To direct the Secretary of Health and Human Services and other Federal
officials to compile into a searchable database information relating to
Federal support for biomedical research and development related to
COVID-19, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Taxpayer Research and Coronavirus
Knowledge Act of 2020''.
SEC. 2. DATABASE.
(a) In General.--The Secretary of Health and Human Services, the
Director of the National Institutes of Health, the Assistant Secretary
for Preparedness and Response of the Department of Health and Human
Services, the Director of the Biomedical Advanced Research and
Development Authority, the Secretary of Defense, the Secretary of
Veterans Affairs, the Director of the National Institute of Allergy and
Infectious Diseases, and such other Federal officials as the Secretary
of Health and Human Services determines to be relevant, acting in
coordination, shall--
(1) compile into a searchable database information relating
to Federal support (before or after the date of enactment of
this Act) for biomedical research and development related to
COVID-19 (including biomedical research and development
relating to a product or therapy that was later modified or
repurposed to be used for COVID-19); and
(2) make such database available on the public website of
the Department of Health and Human Services.
(b) Covered Information.--The information relating to Federal
support referred to in subsection (a)(1) includes all contracts,
funding agreements, licensing arrangements, other transactions, and
other arrangements entered into by the Federal Government and tax
benefits provided with respect to research and development, and
manufacturing, of a drug (including biological products), cell or gene
therapy, or medical device intended to be manufactured, used, designed,
developed, modified, repurposed, licensed, or procured to diagnose,
mitigate, prevent, treat, or cure COVID-19, including but not limited
to the following:
(1) Licensing agreements pursuant to section 207 of title
35, United States Code.
(2) Cooperative research and development agreements and
licensing agreements pursuant to section 3710a of title 15,
United States Code.
(3) Funding agreements, as defined under section 201 of
title 35, United States Code.
(4) Other transactions entered into pursuant to the
following statutes:
(A) Section 319L of the Public Health Service Act
(42 U.S.C. 247d-7e).
(B) Section 105 of the National Institutes of
Health Reform Act of 2006 (42 U.S.C. 284n).
(C) Section 480 of the Public Health Service Act
(42 U.S.C. 287a).
(D) Section 421 of the Public Health Service Act
(42 U.S.C. 285b-3).
(E) Section 2371 of title 10, United States Code.
(5) Tax credits and deductions associated with--
(A) qualified clinical testing expenses, as defined
under section 45C of title 26, United States Code;
(B) qualified research expenses, as defined under
section 41 of title 26, United States Code; and
(C) charitable contributions, as defined under
section 170(c) of title 26, United States Code, to
patient assistance programs.
(c) Information Required.--Notwithstanding any other provision of
law, the Federal officials referred to in subsection (a) shall include
in the database under subsection (a), with regard to each contract,
funding agreement, licensing arrangement, other transaction, other
arrangement, or tax benefit described in subsection (b), at least the
following information:
(1) The agency, program, institute, or other Federal
Government entity providing the Federal support.
(2) The amount and period of Federal financial support with
an itemized breakdown.
(3) Other Federal nonfinancial support, including but not
limited to the use of Federal personnel, Federal facilities,
and Federal equipment.
(4) The grant number, if applicable.
(5) Associated clinical trial data, upon trial completion.
(6) Associated patents and patent applications,
specifying--
(A) any Federal ownership in such patents and
patent applications;
(B) the expiration date of such patents and filing
dates of such patent applications; and
(C) the numbers of such patents and patent
applications.
(7) Associated periods of marketing exclusivity under
Federal law and the durations of such periods.
(8) The corporation, nonprofit organization, academic
institution, person, or other entity receiving the Federal
support.
(9) Any products (including repurposed products) approved,
authorized, or cleared for marketing, or for which marketing
approval, authorization, or clearance is being sought, the
development of which was aided by Federal support, including--
(A) the names of such products;
(B) the prices of such products; and
(C) the current and anticipated manufacturing
capacity to produce such products.
(10) The full terms of the contract, funding agreement,
licensing arrangement, other transaction, or other arrangement
described in subsection (b).
(d) Format of Information.--The database under subsection (a) shall
be--
(1) searchable and filterable according to the categories
of information described in subsection (c); and
(2) presented in a user-friendly format.
(e) Timing.--The database under subsection (a) shall be--
(1) made publicly available not later than 1 month of the
date of enactment of this Act; and
(2) updated not less than every 2 weeks.
(f) Disclosure.--
(1) In general.--Notwithstanding any other provision of
law, to the extent necessary for an official referred to in
subsection (a) to carry out this section, such official may
require entities receiving Federal support referred to in
subsection (a)(1) to disclose to the official any information
relating to such Federal support and required to be included in
the database under subsection (a).
(2) Penalty for nondisclosure.--If an entity that is
required to disclose information pursuant to paragraph (1)
fails to disclose such information within a reasonable period
of time or within two weeks of the official requesting such
information, whichever is sooner, then such entity and all
executive officers employed by such entity shall no longer be
eligible for the receipt of Federal support in the form of a
contract, funding agreement, licensing arrangement, other
transaction, or other arrangement.
<all>